ZA200602153B - Selection system containing non-antibiotic resistance selection marker - Google Patents
Selection system containing non-antibiotic resistance selection marker Download PDFInfo
- Publication number
- ZA200602153B ZA200602153B ZA200602153A ZA200602153A ZA200602153B ZA 200602153 B ZA200602153 B ZA 200602153B ZA 200602153 A ZA200602153 A ZA 200602153A ZA 200602153 A ZA200602153 A ZA 200602153A ZA 200602153 B ZA200602153 B ZA 200602153B
- Authority
- ZA
- South Africa
- Prior art keywords
- gene
- arad
- vector
- deficient
- plasmid
- Prior art date
Links
- 239000003550 marker Substances 0.000 title claims description 30
- 230000001937 non-anti-biotic effect Effects 0.000 title description 3
- 101150017736 araD gene Proteins 0.000 claims description 128
- 239000013612 plasmid Substances 0.000 claims description 118
- 108090000623 proteins and genes Proteins 0.000 claims description 75
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 65
- 241000588724 Escherichia coli Species 0.000 claims description 63
- 239000013598 vector Substances 0.000 claims description 37
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 33
- 230000001580 bacterial effect Effects 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 30
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 27
- 230000002950 deficient Effects 0.000 claims description 24
- 230000000295 complement effect Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 108090000416 L-ribulose-5-phosphate 4-epimerases Proteins 0.000 claims description 18
- 239000001963 growth medium Substances 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 230000010076 replication Effects 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 12
- 108020004705 Codon Proteins 0.000 claims description 11
- 241000388186 Deltapapillomavirus 4 Species 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 238000004873 anchoring Methods 0.000 claims description 9
- 101150091615 sgbE gene Proteins 0.000 claims description 7
- 101150066128 ulaF gene Proteins 0.000 claims description 7
- 101710125507 Integrase/recombinase Proteins 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 241001631646 Papillomaviridae Species 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000004568 DNA-binding Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 58
- 239000002609 medium Substances 0.000 description 44
- 229930027917 kanamycin Natural products 0.000 description 43
- 229960000318 kanamycin Drugs 0.000 description 43
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 43
- 229930182823 kanamycin A Natural products 0.000 description 43
- 239000000047 product Substances 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 40
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 37
- 238000003752 polymerase chain reaction Methods 0.000 description 31
- 230000012010 growth Effects 0.000 description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 229940041514 candida albicans extract Drugs 0.000 description 17
- 239000012138 yeast extract Substances 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000008488 polyadenylation Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000001727 glucose Nutrition 0.000 description 8
- 229960001031 glucose Drugs 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- FNZLKVNUWIIPSJ-UHFFFAOYSA-N Rbl5P Natural products OCC(=O)C(O)C(O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHFFFAOYSA-N 0.000 description 6
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 6
- 239000006152 selective media Substances 0.000 description 6
- FNZLKVNUWIIPSJ-UHNVWZDZSA-N D-ribulose 5-phosphate Chemical compound OCC(=O)[C@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHNVWZDZSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000714474 Rous sarcoma virus Species 0.000 description 5
- 101150076211 TH gene Proteins 0.000 description 5
- 101150003725 TK gene Proteins 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 108010006025 bovine growth hormone Proteins 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 108010041986 DNA Vaccines Proteins 0.000 description 4
- 229940021995 DNA vaccine Drugs 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- 235000019157 thiamine Nutrition 0.000 description 4
- 239000011721 thiamine Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 240000000220 Panda oleosa Species 0.000 description 3
- 235000016496 Panda oleosa Nutrition 0.000 description 3
- 108700003859 araC Genes Proteins 0.000 description 3
- 101150044616 araC gene Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FNZLKVNUWIIPSJ-RFZPGFLSSA-N D-xylulose 5-phosphate Chemical compound OCC(=O)[C@@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-RFZPGFLSSA-N 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108091060545 Nonsense suppressor Proteins 0.000 description 2
- 108090001066 Racemases and epimerases Proteins 0.000 description 2
- 102000004879 Racemases and epimerases Human genes 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000004108 pentose phosphate pathway Effects 0.000 description 2
- 238000013492 plasmid preparation Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CDVZCUKHEYPEQS-AZIZVCISSA-N (2r,3s,4s)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@H](O)[C@H](O)[C@@H](O)C=O CDVZCUKHEYPEQS-AZIZVCISSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 125000003599 L-arabinosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)CO1)* 0.000 description 1
- FNZLKVNUWIIPSJ-CRCLSJGQSA-N L-ribulose 5-phosphate Chemical compound OCC(=O)[C@@H](O)[C@@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-CRCLSJGQSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000003450 growing effect Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000027086 plasmid maintenance Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 108700017804 supF tRNA Proteins 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- 229940074389 tellurium Drugs 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20031319A FI116068B (fi) | 2003-09-15 | 2003-09-15 | Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200602153B true ZA200602153B (en) | 2007-07-25 |
Family
ID=27838984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200602153A ZA200602153B (en) | 2003-09-15 | 2006-03-14 | Selection system containing non-antibiotic resistance selection marker |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7521182B2 (ko) |
| EP (2) | EP1664305B1 (ko) |
| JP (1) | JP4732348B2 (ko) |
| KR (1) | KR101215245B1 (ko) |
| CN (1) | CN1882692B (ko) |
| AP (1) | AP1993A (ko) |
| AU (1) | AU2004272776B2 (ko) |
| BR (1) | BRPI0414392A (ko) |
| CA (1) | CA2538863C (ko) |
| DK (1) | DK1664305T3 (ko) |
| EA (1) | EA011823B1 (ko) |
| ES (1) | ES2529346T3 (ko) |
| FI (1) | FI116068B (ko) |
| HK (2) | HK1084975A1 (ko) |
| IL (1) | IL173923A0 (ko) |
| MX (1) | MXPA06002559A (ko) |
| NZ (1) | NZ545937A (ko) |
| PL (1) | PL1664305T3 (ko) |
| PT (1) | PT1664305E (ko) |
| SI (1) | SI1664305T1 (ko) |
| WO (1) | WO2005026364A1 (ko) |
| ZA (1) | ZA200602153B (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135457A1 (en) * | 2004-08-13 | 2006-06-22 | Yvonne Paterson | Methods for constructing antibiotic resistance free vaccines |
| WO2006017856A2 (en) | 2004-08-13 | 2006-02-16 | The Trustees Of The University Of Pennsylvania | Methods for constructing antibiotic resistance free vaccines |
| BR112014014950B1 (pt) * | 2011-12-21 | 2022-03-29 | Bionet-Asia, Co. Ltd | Cepa de bordetella pertussis geneticamente modificada, e, métodos para produzir uma cepa de bordetella pertussis modificada e para produzir antígenos de bordetella pertussis |
| WO2014018602A1 (en) * | 2012-07-26 | 2014-01-30 | Glycos Biotechnologies, Inc. | Strains and methods for plasmid maintenance |
| WO2014118385A1 (en) | 2013-02-04 | 2014-08-07 | University of Tromsø | The use of dna sequences encoding an interferon as vaccine adjuvants |
| JP2017512500A (ja) | 2014-03-25 | 2017-05-25 | ギンゴー バイオワークス， インコーポレイテッド | 細胞工学のための方法および遺伝システム |
| EP3569710A1 (en) * | 2018-05-16 | 2019-11-20 | BioVersys AG | Bacterial vectors for genetic manipulation of bacteria |
| CN109136247B (zh) * | 2018-08-09 | 2022-03-29 | 天津大学 | 一种用于铅结合蛋白定向进化的双向筛选系统构建方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843760A (en) | 1994-04-15 | 1998-12-01 | Midwest Research Institute | Single zymomonas mobilis strain for xylose and arabinose fermentation |
| SG119177A1 (en) | 1994-12-09 | 2006-02-28 | Imp College Innovations Ltd | Identification of genes |
| HUP9801871A3 (en) | 1995-04-24 | 1999-12-28 | Chromaxome Corp San Diego | Methods for generating and screening novel metabolic pathways |
| FR2738842B1 (fr) | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
| US6479279B2 (en) | 1995-12-29 | 2002-11-12 | Estonian Biocentre | Episomal vectors and uses thereof |
| US6162433A (en) | 1996-04-19 | 2000-12-19 | Medeva Europe Limited | Non antibiotic selectable markers for live vaccines |
| JP2000516472A (ja) | 1996-08-16 | 2000-12-12 | メディカル リサーチ カウンシル | 組織特異的遺伝子発現を与える自己複製型エピソーム性発現ベクター |
| WO1998011231A1 (en) | 1996-09-10 | 1998-03-19 | The Rockefeller University | Highly regulable promoter for heterologous gene expression |
| KR100230578B1 (ko) | 1997-07-25 | 1999-12-01 | 허영섭 | 포스포리불로키나제를 융합파트너로 이용하는 재조합 인간 부갑상선호르몬의 발현벡터 |
| US6291245B1 (en) * | 1998-07-15 | 2001-09-18 | Roche Diagnostics Gmbh | Host-vector system |
| US6368793B1 (en) | 1998-10-14 | 2002-04-09 | Microgenomics, Inc. | Metabolic selection methods |
| CA2404046C (en) | 2000-03-24 | 2008-06-03 | Xoma Technology Ltd. | Improved methods and cells for expression of recombinant protein products |
| PL206097B1 (pl) | 2001-05-03 | 2010-06-30 | Fit Biotech Oyj Plc | Wektor ekspresyjny, jego zastosowanie, sposób wytwarzania tego wektora, komórka gospodarza, kompozycja farmaceutyczna, szczepionka DNA, genowy czynnik terapeutyczny oraz sposób wytwarzania szczepionki DNA |
-
2003
- 2003-09-15 FI FI20031319A patent/FI116068B/fi not_active IP Right Cessation
-
2004
- 2004-09-15 NZ NZ545937A patent/NZ545937A/xx not_active IP Right Cessation
- 2004-09-15 ES ES04767054.2T patent/ES2529346T3/es active Active
- 2004-09-15 PT PT47670542T patent/PT1664305E/pt unknown
- 2004-09-15 EP EP04767054.2A patent/EP1664305B1/en active Active
- 2004-09-15 AU AU2004272776A patent/AU2004272776B2/en not_active Ceased
- 2004-09-15 MX MXPA06002559A patent/MXPA06002559A/es active IP Right Grant
- 2004-09-15 JP JP2006526650A patent/JP4732348B2/ja not_active Expired - Fee Related
- 2004-09-15 WO PCT/FI2004/000540 patent/WO2005026364A1/en active Application Filing
- 2004-09-15 BR BRPI0414392-2A patent/BRPI0414392A/pt not_active Application Discontinuation
- 2004-09-15 CA CA2538863A patent/CA2538863C/en not_active Expired - Fee Related
- 2004-09-15 CN CN2004800336943A patent/CN1882692B/zh not_active Expired - Fee Related
- 2004-09-15 EP EP14191756.7A patent/EP2949753A1/en not_active Withdrawn
- 2004-09-15 US US10/531,870 patent/US7521182B2/en not_active Expired - Fee Related
- 2004-09-15 DK DK04767054.2T patent/DK1664305T3/en active
- 2004-09-15 EA EA200600585A patent/EA011823B1/ru not_active IP Right Cessation
- 2004-09-15 SI SI200432219T patent/SI1664305T1/sl unknown
- 2004-09-15 AP AP2006003577A patent/AP1993A/xx active
- 2004-09-15 PL PL04767054T patent/PL1664305T3/pl unknown
-
2006
- 2006-02-23 IL IL173923A patent/IL173923A0/en unknown
- 2006-03-14 ZA ZA200602153A patent/ZA200602153B/en unknown
- 2006-03-14 KR KR1020067005158A patent/KR101215245B1/ko active IP Right Grant
- 2006-06-27 HK HK06107273.7A patent/HK1084975A1/xx not_active IP Right Cessation
-
2016
- 2016-05-05 HK HK16105149.1A patent/HK1217111A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200602153B (en) | Selection system containing non-antibiotic resistance selection marker | |
| US7416859B2 (en) | Rhodococcus cloning and expression vectors | |
| Aono et al. | Cloning of organic solvent tolerance gene ostA that determines n-hexane tolerance level in Escherichia coli | |
| Meyer et al. | Properties of R1162, a broad-host-range, high-copy-number plasmid | |
| KR102303832B1 (ko) | 내산성을 갖는 효모 세포, 상기 효모 세포를 제조하는 방법 및 이의 용도 | |
| Grossman et al. | Mutations in the rpoH (htpR) gene of Escherichia coli K-12 phenotypically suppress a temperature-sensitive mutant defective in the sigma 70 subunit of RNA polymerase | |
| Kiatpapan et al. | Characterization of pRGO1, a plasmid from Propionibacterium acidipropionici, and its use for development of a host-vector system in propionibacteria | |
| US4725535A (en) | Promoter probe vectors | |
| Rasmussen et al. | Conditional change of DNA replication control in an RNA polymerase mutant of Escherichia coli | |
| JP3592350B2 (ja) | ＡａｔＩＩ制限エンドヌクレアーゼ及びメチラーゼのクローニング及び産生方法並びに制限エンドヌクレアーゼの過剰発現関連方法 | |
| US5872238A (en) | Thermophile gene transfer | |
| JP2752092B2 (ja) | Ｄｅｏプロモーターを有する発現プラスミド及び該プラスミドを含む細菌宿主 | |
| Gowrishankar et al. | Molecular cloning of pheR in Escherichia coli K-12 | |
| Duran | New shuttle vectors for Rhodococcus sp. R312 (formerly Brevibacterium sp. R312), a nitrile hydratase producing strain | |
| Ladygin et al. | Transformation of Chlamydomonas reinhardtii CW-15 with the hygromycin phosphotransferase gene as a selectable marker | |
| Wada et al. | Control of F plasmid replication by a host gene: evidence for interaction of the mafA gene product of Escherichia coli with the mini-F incC region | |
| US5786174A (en) | Thermophile gene transfer | |
| JP3910248B2 (ja) | トランスポゼースを用いるｉｎ ｖｉｔｒｏ反応によるＤＮＡ入れ子型欠失の作製方法 | |
| Brana et al. | Stability of the hybrid plasmid pIM138 and its curing by some eliminating agents | |
| Zuberi et al. | A mutation in P23, the first gene in the RNA polymerase sigma A (sigma 43) operon, affects sporulation in Bacillus subtilis | |
| CA3208968A1 (en) | Target protein production method | |
| Hermanova et al. | Plasmids of Selenomonas ruminantium and development of host-vector system | |
| Helmer | A GENETIC AND KINETIC ANALYSIS OF THE TRK TRANSPORT SYSTEM OF ESCHERICHIACOLI K12. | |
| Kang | Cloning of RNAI Gene from Saccharomyces cerevisiae |